KM Utzschneider, J Tong, B Montgomery, J … - Diabetes care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 22 subjects with IFG (11 female and 11
male, mean ± SD age 59.6 ± 11.5 years) were treated orally with 100 mg vildagliptin once daily
in a single-blind study. Subjects received placebo for 2 weeks (run-in) followed by ... Cited by 22 - Related articles - BL Direct - All 9 versions
- ►endojournals.org A Mari, WA Scherbaum, PM Nilsson, G Lalanne, … - Journal of Clinical …, 2008 - Endocrine Soc Design: A 52-wk double-blind, randomized, parallel-group study comparing vildagliptin (50 mg
every day) and placebo was conducted in 306 patients with mild hyperglycemia (glycosylated
hemoglobin of 6.2–7.5%). Plasma glucose and C-peptide levels were measured during ... Cited by 19 - Related articles - BL Direct - All 4 versions
CE Watson, MA Ligueros-Saylan, JE Foley, JJ Holst … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS — A total of 22 subjects with IFG (11 female and 11
male, mean SD age 59.6 11.5 years) were treated orally with 100 mg vildagliptin once daily in
a single-blind study. Subjects received placebo for 2 weeks (run-in) followed by ... Related articles
YL He, R Sabo, G Sunkara, MN Bizot, GJ … - The Journal of …, 2007 - jclinpharm.highwire.org Vildagliptin is a novel antidiabetic agent that is an orally active, potent, and selective inhibitor
of dipeptidyl peptidase IV, the enzyme responsible for degradation of the incretin hormones.
This open-label, randomized, 3-period crossover study investigated the potential for ... Cited by 8 - Related articles - BL Direct - All 10 versions
YL He, Y Wang, JM Bullock, CF Deacon, … - The Journal of …, 2007 - jclinpharm.highwire.org This randomized, open-label, placebo-controlled, 7-period crossover study assessed dose-response
relationships following single oral doses (10-400 mg) of vildagliptin in 16 patients with type 2
diabetes mellitus. Plasma levels of parent drug, dipeptidyl peptidase-4 activity, glucose, ... Cited by 31 - Related articles - BL Direct - All 6 versions
WA Scherbaum, A Schweizer, A Mari, PM … - Diabetes Obes …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 24 - Related articles - All 2 versions
YL He, R Sabo, GJ Riviere, G Sunkara, S … - Current Medical …, 2007 - informahealthcare.com Yan-ling hea, ron sabob, Gilles-Jacques rivierec, Gangadhar sunkarab, selene leonb, Monica
ligueros- saylanb, Mitchell rosenbergd, William p. dolea and dan howardb ... Address for
correspondence: Dr Yan-Ling He, Exploratory Development-DMPK, Novartis Institutes for ... Cited by 10 - Related articles - BL Direct - All 6 versions
RE Pratley, A Schweizer, J Rosenstock, JE … - Diabetes Obes …, 2008 - interscience.wiley.com Methods: Data from all double-blind, multicentre, randomized, placebo- or active-controlled trials
conducted in drug-naïve patients with T2DM were pooled from all patients receiving monotherapy
with vildagliptin (100 mg daily: 50 mg twice daily or 100 mg once daily, n = 1855) or ... Cited by 9 - Related articles - All 2 versions
WA Scherbaum, A Schweizer, A Mari, PM … - Diabetes Obes …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 19 - Related articles - All 3 versions
[CITATION] American Heart Association, Hypertension, and Obesity in Youth Committee; …
BW McCrindle, EM Urbina, BA Dennison… - Drug therapy of high-risk lipid …, 2007 Cited by 3 - Related articles
